Back to all studies
TerminatedISRCTN42386710

A double blind placebo controlled discontinuation of citalopram in adolescents with major depression

This study has public registry information. It focuses on depression and currently lists study information in Canada.

DepressionOtherFrom 13 Years to 18 Years
In plain English

Key information made simple

This public ISRCTN record appears to relate to depression. HopeStage keeps this listing available so people can review the official source, understand the basic study status, and decide what questions to ask before contacting the research team.

What to expect

Your next step

The public record does not provide enough detail to summarize the visit format or participation steps clearly. Check the official source for the exact eligibility criteria, locations, contact details, and current recruiting status before taking any next step.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: ISRCTN42386710. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may help improve understanding of your condition.

It requires a lighter follow-up, often with questionnaires or check-ins.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
Sunnybrook and Women's College Health Sciences Centre (Canada)
Sponsor type
University
Main activity
behavioral or lifestyle intervention
Time commitment
multiple visits or assessments
Study phase
Not available
Enrollment
Not available
Recruitment status
Terminated
Source
Official registry link
FAQ

Questions about this study

What is A double blind placebo controlled discontinuation of citalopram in adolescents with major depression?

This study is exploring behavioral or lifestyle intervention for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Sunnybrook and Women's College Health Sciences Centre (Canada). Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve behavioral or lifestyle intervention, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

A double blind placebo controlled discontinuation. — Depression Clinical Trial | HopeStage